| Popis: |
Testicular germ cell tumors have an excellent prognosis for disease-specifi c survival ranging from 99% to 73% in patients with localized disease and metastatic disease, respectively. Tumor biology, and in particular, the proper use of multidisciplinary treatment have infl uenced these outcomes. Patients with classic stage I seminoma not candidates for active surveillance can benefi t with 1-2 cycles of carboplatin with less early toxicity versus radiotherapy. In stage I non-seminomatous high-risk tumors, using 1 cycle of a BEP chemotherapy protocol seems superior to lymphadenectomy, but the latter is an appropriate option in experienced centers, if the patient does not want chemotherapy. In patients with stage II and III, the standard therapy after orchiectomy is chemotherapy with BEP, 3-4 cycles depending on risk, reserving surgery for residual disease. |
